Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Neurology

Women

Other Health

Pharmaceutical

Biotechnology

Lilly

More Like This

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Epsilogen Completes £12.5 Million Series B Financing Expansion